What's in Xuanzhu Biopharmaceutical Co., Ltd.'s pipeline?

Xuanzhu Biopharmaceutical Co., Ltd. has 17 drugs in our index: 2 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 11 in Phase 1.

Which companies overlap with Xuanzhu Biopharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: AstraZeneca, Pfizer, Amgen, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xuanzhu-biopharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Xuanzhu Biopharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Xuanzhu Biopharmaceutical Co., Ltd. pipeline: 2 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 0 Phase 2 11 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
XZP-5610 Tablet for "Part C2"	XZP-5610 Tablet for "Part C2"	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]
Anelazol Sodium Enteric-coated Tablets	Anelazol Sodium Enteric-coated Tablets	marketed	Leukotriene inhibitor / Anti-inflammatory agent	Leukotriene synthesis pathway	Immunology / Inflammatory diseases
XZP-3287+Fulvestrant	XZP-3287+Fulvestrant	phase 3	SERD	Estrogen receptor	Oncology
XZP-3621	XZP-3621	phase 3
Placebo + Letrozole/Anastrozole	Placebo + Letrozole/Anastrozole	phase 3	Aromatase inhibitor	Aromatase	Oncology
XZP-3287+ Letrozole/Anastrozole	XZP-3287+ Letrozole/Anastrozole	phase 3	Aromatase inhibitor combination		Oncology

Therapeutic area mix

Oncology · 3
Immunology / Inflammatory diseases · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 2 shared drug classes
Pfizer · 2 shared drug classes
Amgen · 1 shared drug class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
Boehringer Ingelheim · 1 shared drug class
Assiut University · 1 shared drug class
ANI Pharmaceuticals · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Xuanzhu Biopharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Xuanzhu Biopharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xuanzhu-biopharmaceutical-co-ltd. Accessed 2026-05-16.